Renal Implications of Psoriasis: Urinary Podocyte Markers and Disease Progression

Sule  Gencoglu; Meltem  Yardim; Ramazan Fazil Akkoc

doi:10.5826/dpc.1502a4910

Renal Implications of Psoriasis: Urinary Podocyte Markers and Disease Progression

Authors

Sule Gencoglu Department of Dermatology, Gozde Academy Hospital, Malatya, Turkey https://orcid.org/0000-0001-9057-6625
Meltem Yardim Department of Medical Biochemistry, Yerkoy State Hospital, Yozgat, Turkey
Ramazan Fazil Akkoc Department of Anatomy, Faculty of Medicine, Firat University, Elazig, Turkey https://orcid.org/0000-0002-0559-8932

Keywords:

Psoriasis vulgaris, Podocytes, Podocalyxin, Nephrin, Albuminuria

Abstract

Introduction: Psoriasis may lead to glomerular inflammatory damage and disruption of the podocyte barrier, allowing podocyte degradation products to leak into the urine.

Objectives: We aimed to analyze the concentrations of podocyte surface glycoprotein podocalyxin (PDX) and podocyte slit protein nephrin in spot urine samples of patients diagnosed with mild, moderate, or severe psoriasis vulgaris.

Methods: A total of 78 participants, including 58 patients diagnosed with mild, moderate, or severe psoriasis vulgaris and 20 controls, were included in the study. The diagnosis of psoriasis was made considering the typical morphological appearance of the lesions. Morning urine samples were used to evaluate urine PDX and nephrin levels. Albuminuria was evaluated by calculating the albumin-creatinine ratio (uACR).

Results: Urinary PDX and nephrin levels of psoriasis groups were significantly higher than the control group. Urinary PDX and nephrin levels of mild and moderate psoriasis groups were similar but higher than the control group. Urinary PDX and nephrin levels of the severe psoriasis group were significantly higher than the mild and moderate psoriasis groups. Microalbuminuria rates were similar in the psoriasis and control groups. A positive significant correlation was detected between urine PDX, nephrin, uACR, and SBP. After adjustment for age, BMI and gender, urine PDX and nephrin were found to be independent risk factors for microalbuminuria.

Conclusion: This study showed that podocyte damage in psoriasis patients begins in the early stage of the disease and increases significantly in the severe stage of the disease.

References

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated Comorbidity (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. DOI: 10.1038/jid.2012.339. PMID: 23014338.

Chi CC, Wang J, Chen YF, Wang SH, Chen FL, Tung TH. Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: a nationwide population-based cohort study. J Dermatol Sci. 2015;78(3):232–238. DOI: 10.1016/j.jdermsci.2015.03.012. PMID: 25862150.

Chiu HY, Huang HL, Li CH, et al. Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: A nationwide population-based cohort study. Br J Dermatol. 2015;173(1):146–154. DOI: 10.1111/bjd.13599. PMID: 25511692.

Svedbom A, Dalén J, Mamolo C, et al. Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study. Acta Derm Venereol. 2015;95(7):809–815. DOI: 10.2340/00015555-2095. PMID: 25766866.

Jabbar-Lopez ZK, Weatherhead SC, Reynolds NJ. Kidney disease in moderate-to-severe psoriasis: a critical appraisal. Br J Dermatol. 2016;174(2):267–270. DOI: 10.1111/bjd.14302. PMID: 26871922.

Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ. 2013;347:f5961. DOI: 10.1136/bmj.f5961. PMID: 24129480.

Ren F, Zhang M, Zhang C, Sang H. Psoriasis-Like Inflammation Induced Renal Dysfunction through the TLR/NF-κB Signal Pathway. Biomed Res Int. 2020;2020:3535264. DOI: 10.1155/2020/3535264. PMID: 32090080.

Kerjaschki D, Sharkey DJ, Farquhar MG. Identification and characterization of podocalyxin--the major sialoprotein of the renal glomerular epithelial cell. J Cell Biol. 1984;98(4):1591–1596. DOI: 10.1083/jcb.98.4.1591. PMID: 6371025.

Satchell SC, Braet F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol. 2009;296(5):F947–956. DOI: 10.1152/ajprenal.90601.2008. PMID: 19129259.

Skoberne A, Konieczny A, Schiffer M. Glomerular epithelial cells in the urine: what has to be done to make them worthwhile? Am J Physiol Renal Physiol. 2009;296(2):F230–241. DOI: 10.1152/ajprenal.90507.2008. PMID: 18842819.

Jha JC, Thallas-Bonke V, Banal C, et al. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy. Diabetologia. 2016;59(2):379–389. DOI: 10.1007/s00125-015-3796-0. PMID: 26508318.

Ren F, Zhang M, Hao L, Sang H. Kidney involvement in psoriasis: a case-control study from China. Int Urol Nephrol. 2017;49(11):1999–2003. DOI: 10.1007/s11255-017-1692-x. PMID: 28939941.

Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. DOI: 10.1016/S0140-6736(14)61909-7. PMID: 26025581.

Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis. Ottawa, ON: Canadian Dermatology Association; 2009.

Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271. DOI: 10.1016/S0140-6736(07)61128-3. PMID: 17658397.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419. DOI: 10.1007/BF00280883. PMID: 3899825.

Olivoto T, Lucio AD. Metan: An R package for multi-environment trial analysis. Methods Ecol Evol. 2020;11(6):783–789. DOI: 10.1111/2041-210X.13384.

Wang Y, Zhao S, Loyd S, Groome LJ. Increased urinary excretion of nephrin, podocalyxin, and βig-h3 in women with preeclampsia. Am J Physiol Renal Physiol. 2012;302(9):F1084-9. DOI: 10.1152/ajprenal.00597.2011. PMID: 22301621.

Bergler-Czop B, Brzezińska-Wcisło L. Serum markers of insulin resistance in psoriasis. Postepy Dermatol Alergol. 2014;31(2):77–81. DOI: 10.5114/pdia.2014.40810. PMID: 24790518.

Naldi L, Gambardella A, Svensson Å, et al. Prevalence of metabolic syndrome and related comorbidities in patients with psoriasis: a cross-sectional study from the Italian psocare project. Br J Dermatol. 2013;169(6):1273–1279. DOI: 10.1111/bjd.12567. PMID: 23905877.

Neimann AL, Shin DB, Kiseljak-Vassiliades K, Noe MH, Dozmorov I, Gelfand JM. Psoriasis is associated with independent risk of diabetes mellitus. Results from the National Psoriasis Foundation Case-Control Study. J Am Acad Dermatol. 2011;65(1):98–103.e1–3. DOI: 10.1016/j.jaad.2010.12.022. PMID: 21300407.

Sommer DM, Jenisch L, Suchan M, Christophers E, Weichenmeier I. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006;298(7):321–328. DOI: 10.1007/s00403-006-0691-z. PMID: 17006528.